139 related articles for article (PubMed ID: 21801225)
1. Is it safe to use erythropoiesis-stimulating agents to treat anemia in chronic kidney disease patients with active malignancies?
Gupta G; Choi MJ
Semin Dial; 2011; 24(4):379-81. PubMed ID: 21801225
[No Abstract] [Full Text] [Related]
2. Triumph and tragedy: anemia management in chronic kidney disease.
Novak JE; Szczech LA
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
[TBL] [Abstract][Full Text] [Related]
3. Quality of life in CKD patients treated with erythropoiesis-stimulating agents.
Parfrey PS; Wish T
Am J Kidney Dis; 2010 Mar; 55(3):423-5. PubMed ID: 20189050
[No Abstract] [Full Text] [Related]
4. Editorial perspective. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?
Parfrey PS
Am J Nephrol; 2010; 31(6):565-6. PubMed ID: 20501992
[No Abstract] [Full Text] [Related]
5. Debate: PRO Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?
Singh AK
Am J Nephrol; 2010; 31(6):552-6; discussion 563-4. PubMed ID: 20501988
[No Abstract] [Full Text] [Related]
6. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease.
Vaziri ND; Zhou XJ
Nephrol Dial Transplant; 2009 Apr; 24(4):1082-8. PubMed ID: 18987263
[No Abstract] [Full Text] [Related]
7. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
Singh AK
J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
[No Abstract] [Full Text] [Related]
8. ESAs in dialysis patients: are you a hedgehog or a fox?
Singh AK
J Am Soc Nephrol; 2010 Apr; 21(4):543-6. PubMed ID: 20357173
[No Abstract] [Full Text] [Related]
9. Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?
Walker RG
Clin J Am Soc Nephrol; 2008 Jul; 3(4):935-7. PubMed ID: 18579671
[No Abstract] [Full Text] [Related]
10. [Would prescription of erythropoiesis-stimulating agents in pre-dialysis change after results from TREAT study?].
Alcázar R; Tato A; García F; Barrios V; Quereda C
Nefrologia; 2010; 30(1):114-8. PubMed ID: 20038963
[No Abstract] [Full Text] [Related]
11. Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.
Doss S; Schiller B
Nephrol Nurs J; 2010; 37(6):617-26. PubMed ID: 21290916
[TBL] [Abstract][Full Text] [Related]
12. Strategies for successfully managing the anemia of chronic kidney disease in the long-term care setting.
Germain MJ
Consult Pharm; 2008 Mar; 23 Suppl A():11-7. PubMed ID: 18454575
[TBL] [Abstract][Full Text] [Related]
13. Adverse consequences with use of erythropoiesis-stimulating agents in anemia prompt release of guidelines to ensure safe use and maximize benefit.
Dharmarajan TS; Widjaja D
Geriatrics; 2008 Jun; 63(6):13-29. PubMed ID: 18512996
[TBL] [Abstract][Full Text] [Related]
14. Evolving regulatory landscape with erythropoiesis-stimulating agents and impact on managed care.
Fatodu H
Am J Manag Care; 2010 Mar; 16 Suppl Issues():S74-9. PubMed ID: 20297875
[TBL] [Abstract][Full Text] [Related]
15. [Anaemia correction in diabetic patients with chronic kidney disease without substitutive treatment: teachings from TREAT study].
de Francisco AL; Aljama P; Arias M; Fernández E; Górriz JL; Gómez JM; Castelao AM; Portolés J
Nefrologia; 2010; 30(1):15-20. PubMed ID: 20038964
[No Abstract] [Full Text] [Related]
16. Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia.
Pedrazzoli P; Rosti G; Secondino S; Siena S
Cancer; 2009 Mar; 115(6):1169-73. PubMed ID: 19152436
[TBL] [Abstract][Full Text] [Related]
17. [Erythropoiesis-stimulating agents in chronic kidney disease: which route of administration?].
Borrelli S; Baldanza D; Scigliano R; Catapano F; Grimaldi M; Calabria M; Zamboli P; Minutolo R; De Nicola L; Conte G
G Ital Nefrol; 2009; 26(1):31-7. PubMed ID: 19255962
[TBL] [Abstract][Full Text] [Related]
18. Erythropoiesis-stimulating agents for anemic patients with cancer.
Sheikh S; Littlewood TJ
Expert Rev Hematol; 2010 Dec; 3(6):697-704. PubMed ID: 21091146
[TBL] [Abstract][Full Text] [Related]
19. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
Singh AK
Clin J Am Soc Nephrol; 2010 Apr; 5(4):553-6. PubMed ID: 20203166
[No Abstract] [Full Text] [Related]
20. Survey of attitude of physicians on updates in the management of anemia in chronic kidney disease patients - an eye-opener.
Binnani PG
Saudi J Kidney Dis Transpl; 2009 Nov; 20(6):1090. PubMed ID: 19861881
[No Abstract] [Full Text] [Related]
[Next] [New Search]
